Psychedelic

Phase 1Small molecule

CCanadian Forces Health Services Centre Ottawa

Psychedelic is one of 7 small molecule programs targeting PTSD. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PTSDActive, not recruiting

PTSDPhase 1

Active, not recruiting

Competition

Competitive Landscape

8 competitors in PTSD

#DrugCompanyPhaseTrials

Nurtec

Pfizer

Approved

—2

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

1 3

Ativan

BBausch Health Americas, Inc.

Approved

1 4

Ritalin

Novartis

Phase 2

1 5

Midomafetamine

LLykos Therapeutics

Phase 3

5 6

Reboxetine

UUniversity of Zurich

Phase 2

1 7

Psychedelic

CCanadian Forces Health Services Centre Ottawa

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

PTSD

NCT07275970

Clinical

Trials by Indication[1]

ESS1 trial

Psychedelic Therapy for Wellness Studies Retrospectively

Unknown status·CCanadian Forces Health Services Centre Ottawa··NCT05469243·100 enrolled

PTSD1 trial

An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD

Active, not recruiting·SSuzanne "Sue" Sisley MD·Phase 1·NCT07275970·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Psychedelic. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Psychedelic compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Psychedelic. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Canadian Forces Health Services Centre Ottawa company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCanadian Forces Health Services Centre Ottawa

Psychedelic

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

ESS1 trial

PTSD1 trial

References

Drug Info

Quick Facts

Related News